

Supplementary Table 1: Treatments characteristics

	ACA (N=115)	SCL 70 (N=91)	
Receiving Corticosteroids – % – (n/N)	9.6 (11/115)	36 (33/91)	p< 0.001
Average dose the week before inclusion – mg [IQR] – (N)	6 [5-7] (115)	5 [5-7] (91)	p= 0.08
Receiving immunosuppressants – % – (n/N)	8.7 (10/115)	38 (35/91)	p< 0.001
Mycophenolate – % – (n/N)	1.5 (1/69)	6.2 (4/65)	p= 0.2
Methotrexate – % – (n/N)	4.3 (3/69)	10.8 (7/65)	p= 0.2
Azathioprine – % – (n/N)	4.3 (3/69)	4.6 (3/65)	p= 1
Cyclophosphamide – % – (n/N)	0 (0/69)	6.2 (4/65)	p= 0.52
Receiving anti-malarials – % – (n/N)	8.7 (10/115)	4.4 (4/91)	p= 0.2
Receiving biologics agents – % – (n/N)	0.9 (1/115)	5.5 (5/91)	p= 0.049
Abatacept – % – (n/N)	1.5 (1/69)	0 (0/65)	p= 1
Tocilizumab – % – (n/N)	0 (0/69)	7.7 (5/65)	p= 0.025
TNF inhibitors – % – (n/N)	1.5 (1/69)	1.5 (1/65)	p= 1

(n/N): number of patients / Total number of patients with available data.